Logo Image

Blood Cancers

Latest News

September 22nd 2021
FDA Approval of Brukinsa in Rare Lymphoma Offers a New Option, Though Will Not Replace Other Therapies

The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.

September 1st 2021

Brukinsa Receives FDA Approval for Treatment of Waldenstrom’s Macroglobulinemia

December 17th 2020

Treating Waldenstrom’s Macroglobulinemia

December 6th 2020

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

June 25th 2018

Drug Duo Granted Priority Review to Treat Waldenstrom Macroglobulinemia